## First-Line Agent in HFrEF: ACE Inhibitors **Key Point:** ACE inhibitors (or ARBs if ACE-I intolerant) are the foundational first-line agents in HFrEF and should be initiated early, even in asymptomatic LV dysfunction (LVEF ≤40%). [cite:Harrison 21e Ch 297] **High-Yield:** The landmark CONSENSUS and SOLVD trials demonstrated that ACE inhibitors reduce mortality, hospitalizations, and slow disease progression in HFrEF. They are Class I recommendations in all stages of HFrEF. ## Rationale for Enalapril 1. **Neurohormonal modulation:** ACE inhibitors block angiotensin II formation, reducing vasoconstriction, sodium retention, and maladaptive remodeling. 2. **Mortality benefit:** Proven reduction in all-cause and cardiovascular mortality. 3. **Timing:** Should be started early, before beta-blockers, in the absence of contraindications (hypotension, hyperkalemia, renal impairment). 4. **Dose titration:** Uptitrate to target dose (e.g., enalapril 10 mg BD) over weeks to months. ## Typical HFrEF Initiation Sequence | Agent | Timing | Rationale | |-------|--------|----------| | **ACE-I/ARB** | **First** | Foundational; mortality benefit; neurohormonal antagonism | | **Beta-blocker** | Second (after ACE-I stabilized) | Reduces sympathetic drive; mortality benefit | | **MRA** | Third (if LVEF ≤40% + symptoms or post-MI) | Aldosterone antagonism; additional mortality benefit | | **Diuretics** | As needed | Symptom relief; no mortality benefit | **Clinical Pearl:** In this euvolemic patient, diuretics are not the first priority—neurohormonal antagonism is. Furosemide would be added only if congestion develops. **Tip:** Remember the mnemonic **ABCD** for HFrEF: **A**CE-I/ARB, **B**eta-blocker, **C**ardiac resynchronization/aldosterone antagonist, **D**iuretics (as needed).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.